Laurence Daheron, Phd, Head of the iPS Core Facility at the Harvard Stem Cell Institute, on gene-editing strategies for iPS-derived cell therapies.
Laurence Daheron, Phd, Head of the iPS Core Facility at the Harvard Stem Cell Institute, discusses the industrial challenges related to cell therapies: manufacturing, safety testing, administration mode.
Laurence Daheron, Phd, Head of the iPS Core Facility at the Harvard Stem Cell Institute, presents the Oncopanel strategy to evaluate the genomic safety of clinical-grade iPS lines.
The webcast In the Stem Cell Jungle becomes a blog about pluripotent stem cells and their applications in cell therapy. Maxime Feyeux, CSO of TreeFrog, who was hosting the webcast on youtube, is now editor of the blog, which brings together developmental biology insights about pluripotent stem cells (both iPS & ES cells) and views from the industry about iPS-derived cell therapies for regenerative medicine and immune-oncology. The blog is also featuring free access resources, such as a whitebook about the epiblast rosette and how to leverage this in vivo structure to manufacture iPSCs at scale using biomimetic technologies such as C-Stem, as well as a list of cell therapy programs based on pluripotent stem cells in clinical trial.